Brief: ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

Niagen Bioscience

07/06/2024 13:59

June 7 (Reuters) - Chromadex Corp  CDXC.O :
    * CHROMADEX RECEIVES EXCLUSIVE U.S. FDA ORPHAN DRUG
DESIGNATION
(ODD) AND RARE PEDIATRIC (RPD) DISEASE DESIGNATION FOR
NICOTINAMIDE RIBOSIDE CHLORIDE (NRC) FOR THE TREATMENT OF ATAXIA
TELANGIECTASIA (AT)
    * CHROMADEX - PLANS TO CONDUCT ADDITIONAL STUDIES ON NRC IN
ANTICIPATION OF FILING FOR AN INVESTIGATIONAL NEW DRUG
APPLICATION (IND) FOR TREATMENT OF AT

Source text for Eikon:  ID:nBw4GDRNca 
Further company coverage:  CDXC.O 

 ((Reuters.Briefs@thomsonreuters.com;))